Systemic Lupus Erythematosus – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Systemic Lupus Erythematosus – Pipeline Review, H2 2017’, provides an overview of the Systemic Lupus Erythematosus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus

The report reviews pipeline therapeutics for Systemic Lupus Erythematosus by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Systemic Lupus Erythematosus therapeutics and enlists all their major and minor projects

The report assesses Systemic Lupus Erythematosus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Ablynx NV

ACEA Biosciences Inc

AiCuris GmbH & Co KG

Amgen Inc

Asahi Kasei Pharma Corp

Atlantic Bio Sci LLC

Aurinia Pharmaceuticals Inc

Bio-Path Holdings Inc

Biogen Inc

Biotest AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Corestem Inc

CuraVac Inc

Deltanoid Pharmaceuticals Inc

Domainex Ltd

Eisai Co Ltd

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Galapagos NV

Genentech Inc

Genosco Inc

Genovax Srl

Gilead Sciences Inc

GlaxoSmithKline Plc

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Idorsia Ltd

Immungenetics AG

Immunomedics Inc

Immunwork Inc

Immupharma Plc

Invion Ltd

Janus Biotherapeutics Inc

Johnson & Johnson

K-Stemcell Co Ltd

Karyopharm Therapeutics Inc

KPI Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

LSK BioPartners Inc

MacroGenics Inc

MedAnnex Ltd

Medestea Research & Production SpA

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Mount Tam Biotechnologies Inc

Nektar Therapeutics

Neovacs SA

Nippon Chemiphar Co Ltd

Novartis AG

Nuevolution AB

Omeros Corp

Pfizer Inc

Principia Biopharma Inc

Ra Pharmaceuticals Inc

RedHill Biopharma Ltd

Sarepta Therapeutics Inc

SBI Biotech Co Ltd

Takeda Pharmaceutical Co Ltd

TheraMAB LLC

TxCell SA

UCB SA

Xencor Inc

XTL Biopharmaceuticals Ltd

Zai Lab Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Systemic Lupus Erythematosus - Overview 11

Systemic Lupus Erythematosus - Therapeutics Development 12

Pipeline Overview 12

Pipeline by Companies 13

Pipeline by Universities/Institutes 19

Products under Development by Companies 20

Products under Development by Universities/Institutes 27

Systemic Lupus Erythematosus - Therapeutics Assessment 28

Assessment by Target 28

Assessment by Mechanism of Action 33

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 42

AbbVie Inc 42

Ablynx NV 42

ACEA Biosciences Inc 43

AiCuris GmbH & Co KG 43

Amgen Inc 43

Asahi Kasei Pharma Corp 44

Atlantic Bio Sci LLC 44

Aurinia Pharmaceuticals Inc 45

Bio-Path Holdings Inc 45

Biogen Inc 46

Biotest AG 46

Boehringer Ingelheim GmbH 47

Bristol-Myers Squibb Co 47

Celgene Corp 48

Corestem Inc 48

CuraVac Inc 49

Deltanoid Pharmaceuticals Inc 49

Domainex Ltd 50

Eisai Co Ltd 50

Eli Lilly and Co 50

F. Hoffmann-La Roche Ltd 51

Galapagos NV 51

Genentech Inc 52

Genosco Inc 52

Genovax Srl 53

Gilead Sciences Inc 53

GlaxoSmithKline Plc 54

HanAll Biopharma Co Ltd 54

Hanmi Pharmaceuticals Co Ltd 55

Idorsia Ltd 55

Immungenetics AG 55

Immunomedics Inc 56

Immunwork Inc 56

Immupharma Plc 57

Invion Ltd 57

Janus Biotherapeutics Inc 58

Johnson & Johnson 58

K-Stemcell Co Ltd 59

Karyopharm Therapeutics Inc 59

KPI Therapeutics Inc 59

Kyowa Hakko Kirin Co Ltd 60

Lead Discovery Center GmbH 60

LSK BioPartners Inc 61

MacroGenics Inc 61

MedAnnex Ltd 62

Medestea Research & Production SpA 62

MedImmune LLC 62

Merck & Co Inc 63

Merck KGaA 63

Millennium Pharmaceuticals Inc 64

Mitsubishi Tanabe Pharma Corp 64

Mount Tam Biotechnologies Inc 65

Nektar Therapeutics 65

Neovacs SA 66

Nippon Chemiphar Co Ltd 66

Novartis AG 67

Nuevolution AB 67

Omeros Corp 68

Pfizer Inc 68

Principia Biopharma Inc 69

Ra Pharmaceuticals Inc 69

RedHill Biopharma Ltd 70

Sarepta Therapeutics Inc 70

SBI Biotech Co Ltd 71

Takeda Pharmaceutical Co Ltd 71

TheraMAB LLC 71

TxCell SA 72

UCB SA 72

Xencor Inc 73

XTL Biopharmaceuticals Ltd 73

Zai Lab Ltd 73

Systemic Lupus Erythematosus - Drug Profiles 75

(clarithromycin + clofazimine + rifabutin) - Drug Profile 75

abatacept - Drug Profile 85

ABS-11 - Drug Profile 94

AC-058 - Drug Profile 95

ACY-1083 - Drug Profile 96

ACY-738 - Drug Profile 97

aldesleukin - Drug Profile 99

aldesleukin - Drug Profile 100

AMG-557 - Drug Profile 101

AMG-570 - Drug Profile 103

amiselimod hydrochloride - Drug Profile 104

anifrolumab - Drug Profile 106

Annexuzlimab - Drug Profile 109

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 110

APT-602 - Drug Profile 111

AT-791 - Drug Profile 112

atacicept - Drug Profile 113

baricitinib - Drug Profile 116

bee venom [Apis mellifera] allergen extract - Drug Profile 128

belimumab - Drug Profile 129

belimumab + rituximab - Drug Profile 137

BI-655064 - Drug Profile 138

BI-705564 - Drug Profile 140

BIIB-059 - Drug Profile 141

BIIB-068 - Drug Profile 142

Bispecific Monoclonal Antibody to Inhibit CD22 and CD20 for Autoimmune Disorders and Oncology - Drug Profile 143

BL-5923 - Drug Profile 144

BMS-986165 - Drug Profile 145

bortezomib - Drug Profile 147

BT-063 - Drug Profile 155

C-15231A - Drug Profile 156

CC-90008 - Drug Profile 158

Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile 159

Cellular Immunotherapy for Epstein-Barr Viral Infections, Multiple Sclerosis and Systemic Lupus Erythematosus - Drug Profile 161

Cellular Immunotherapy to Target CD19 for Oncology and Immunology - Drug Profile 162

cenerimod - Drug Profile 163

CS-20AT04 - Drug Profile 165

dalazatide - Drug Profile 166

dapirolizumab pegol - Drug Profile 171

DMXD-011 - Drug Profile 173

DP-001 - Drug Profile 175

Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile 177

Drugs to Inhibit BAFF and APRIL for Systemic Lupus Erythematosus - Drug Profile 178

E-6446 - Drug Profile 179

edratide - Drug Profile 180

ENTX-LN - Drug Profile 183

evobrutinib - Drug Profile 184

faralimomab - Drug Profile 186

filgotinib - Drug Profile 187

forigerimod acetate - Drug Profile 200

GDC-0853 - Drug Profile 204

GNKS-356 - Drug Profile 206

GS-9876 - Drug Profile 207

GX-101 - Drug Profile 209

HCI-1401 - Drug Profile 210

HE-33 - Drug Profile 211

HL-161 - Drug Profile 212

iberdomide hydrochloride - Drug Profile 213

ICP-022 - Drug Profile 216

IL-233 - Drug Profile 217

IMP-10 - Drug Profile 218

INV-103 - Drug Profile 219

INV-17 - Drug Profile 222

INV-88 - Drug Profile 223

ixazomib citrate - Drug Profile 224

JB-6121 - Drug Profile 235

JNJ-0839 - Drug Profile 236

JNJ-56022473 - Drug Profile 237

KPT-350 - Drug Profile 239

lenabasum - Drug Profile 241

lulizumab pegol - Drug Profile 250

MEDI-7734 - Drug Profile 251

MGD-010 - Drug Profile 252

milatuzumab - Drug Profile 255

mizoribine - Drug Profile 258

NC-2400 - Drug Profile 259

NCS-613 - Drug Profile 260

NKTR-358 - Drug Profile 261

NUE-7770 - Drug Profile 263

obinutuzumab - Drug Profile 265

OMS-721 - Drug Profile 274

P-Dex - Drug Profile 284

PF-06823859 - Drug Profile 285

poseltinib - Drug Profile 286

prexigebersen - Drug Profile 288

PRN-1008 - Drug Profile 295

RA-101495 - Drug Profile 297

RCT-18 - Drug Profile 300

RSLV-132 - Drug Profile 301

RSLV-133 - Drug Profile 303

SBI-9674 - Drug Profile 304

SKIO-703 - Drug Profile 305

SM-03 - Drug Profile 307

SM-934 - Drug Profile 308

Small Molecule to Agonize CD11b for Systemic Lupus Erythematosus - Drug Profile 309

Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile 310

Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile 311

Small Molecules for Respiratory and Immunology - Drug Profile 312

Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 313

Small molecules to Inhibit PAD for Autoimmune Diseases, Multiple Sclerosis and Oncology - Drug Profile 314

Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology, Oncology and Cardiovascular Disease - Drug Profile 316

Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile 318

Synthetic Peptides for Systemic Lupus Erythematosus - Drug Profile 319

TAB-08 - Drug Profile 320

TAK-079 - Drug Profile 323

TAM-01 - Drug Profile 324

TE-2324 - Drug Profile 326

tofacitinib citrate - Drug Profile 327

ustekinumab - Drug Profile 345

Vaccine for Systemic Lupus Erythematosus - Drug Profile 352

Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile 353

venetoclax - Drug Profile 359

VISTA-Ig - Drug Profile 373

vobarilizumab - Drug Profile 374

voclosporin - Drug Profile 380

WITH-1101 - Drug Profile 391

XL-499 - Drug Profile 392

XmAb-5871 - Drug Profile 393

ZL-1101 - Drug Profile 397

Systemic Lupus Erythematosus - Dormant Projects 398

Systemic Lupus Erythematosus - Discontinued Products 404

Systemic Lupus Erythematosus - Product Development Milestones 406

Featured News & Press Releases 406

Appendix 418

Methodology 418

Coverage 418

Secondary Research 418

Primary Research 418

Expert Panel Validation 418

Contact Us 418

Disclaimer 419

List of Tables

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H2 2017 20

Number of Products under Development by Companies, H2 2017 22

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 23

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 24

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 25

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 26

Number of Products under Development by Universities/Institutes, H2 2017 27

Products under Development by Companies, H2 2017 28

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 29

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 30

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 31

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 32

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 33

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 34

Products under Development by Universities/Institutes, H2 2017 35

Number of Products by Stage and Target, H2 2017 37

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 38

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 39

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 40

Number of Products by Stage and Mechanism of Action, H2 2017 42

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 43

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 44

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 45

Number of Products by Stage and Route of Administration, H2 2017 47

Number of Products by Stage and Molecule Type, H2 2017 49

Systemic Lupus Erythematosus – Pipeline by AbbVie Inc, H2 2017 50

Systemic Lupus Erythematosus – Pipeline by Ablynx NV, H2 2017 51

Systemic Lupus Erythematosus – Pipeline by ACEA Biosciences Inc, H2 2017 51

Systemic Lupus Erythematosus – Pipeline by AiCuris GmbH & Co KG, H2 2017 51

Systemic Lupus Erythematosus – Pipeline by Amgen Inc, H2 2017 52

Systemic Lupus Erythematosus – Pipeline by Asahi Kasei Pharma Corp, H2 2017 52

Systemic Lupus Erythematosus – Pipeline by Atlantic Bio Sci LLC, H2 2017 53

Systemic Lupus Erythematosus – Pipeline by Aurinia Pharmaceuticals Inc, H2 2017 53

Systemic Lupus Erythematosus – Pipeline by Bio-Path Holdings Inc, H2 2017 54

Systemic Lupus Erythematosus – Pipeline by Biogen Inc, H2 2017 54

Systemic Lupus Erythematosus – Pipeline by Biotest AG, H2 2017 55

Systemic Lupus Erythematosus – Pipeline by Boehringer Ingelheim GmbH, H2 2017 55

Systemic Lupus Erythematosus – Pipeline by Bristol-Myers Squibb Co, H2 2017 56

Systemic Lupus Erythematosus – Pipeline by Celgene Corp, H2 2017 56

Systemic Lupus Erythematosus – Pipeline by Corestem Inc, H2 2017 57

Systemic Lupus Erythematosus – Pipeline by CuraVac Inc, H2 2017 57

Systemic Lupus Erythematosus – Pipeline by Deltanoid Pharmaceuticals Inc, H2 2017 57

Systemic Lupus Erythematosus – Pipeline by Domainex Ltd, H2 2017 58

Systemic Lupus Erythematosus – Pipeline by Eisai Co Ltd, H2 2017 58

Systemic Lupus Erythematosus – Pipeline by Eli Lilly and Co, H2 2017 59

Systemic Lupus Erythematosus – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 59

Systemic Lupus Erythematosus – Pipeline by Galapagos NV, H2 2017 60

Systemic Lupus Erythematosus – Pipeline by Genentech Inc, H2 2017 60

Systemic Lupus Erythematosus – Pipeline by Genosco Inc, H2 2017 61

Systemic Lupus Erythematosus – Pipeline by Genovax Srl, H2 2017 61

Systemic Lupus Erythematosus – Pipeline by Gilead Sciences Inc, H2 2017 61

Systemic Lupus Erythematosus – Pipeline by GlaxoSmithKline Plc, H2 2017 62

Systemic Lupus Erythematosus – Pipeline by HanAll Biopharma Co Ltd, H2 2017 62

Systemic Lupus Erythematosus – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 63

Systemic Lupus Erythematosus – Pipeline by Idorsia Ltd, H2 2017 63

Systemic Lupus Erythematosus – Pipeline by Immungenetics AG, H2 2017 64

Systemic Lupus Erythematosus – Pipeline by Immunomedics Inc, H2 2017 64

Systemic Lupus Erythematosus – Pipeline by Immunwork Inc, H2 2017 65

Systemic Lupus Erythematosus – Pipeline by Immupharma Plc, H2 2017 65

Systemic Lupus Erythematosus – Pipeline by Invion Ltd, H2 2017 66

Systemic Lupus Erythematosus – Pipeline by Janus Biotherapeutics Inc, H2 2017 66

Systemic Lupus Erythematosus – Pipeline by Johnson & Johnson, H2 2017 66

Systemic Lupus Erythematosus – Pipeline by K-Stemcell Co Ltd, H2 2017 67

Systemic Lupus Erythematosus – Pipeline by Karyopharm Therapeutics Inc, H2 2017 67

Systemic Lupus Erythematosus – Pipeline by KPI Therapeutics Inc, H2 2017 68

Systemic Lupus Erythematosus – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 68

Systemic Lupus Erythematosus – Pipeline by Lead Discovery Center GmbH, H2 2017 69

Systemic Lupus Erythematosus – Pipeline by LSK BioPartners Inc, H2 2017 69

Systemic Lupus Erythematosus – Pipeline by MacroGenics Inc, H2 2017 70

Systemic Lupus Erythematosus – Pipeline by MedAnnex Ltd, H2 2017 70

Systemic Lupus Erythematosus – Pipeline by Medestea Research & Production SpA, H2 2017 70

Systemic Lupus Erythematosus – Pipeline by MedImmune LLC, H2 2017 71

Systemic Lupus Erythematosus – Pipeline by Merck & Co Inc, H2 2017 71

Systemic Lupus Erythematosus – Pipeline by Merck KGaA, H2 2017 72

Systemic Lupus Erythematosus – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 72

Systemic Lupus Erythematosus – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 73

Systemic Lupus Erythematosus – Pipeline by Mount Tam Biotechnologies Inc, H2 2017 73

Systemic Lupus Erythematosus – Pipeline by Nektar Therapeutics, H2 2017 74

Systemic Lupus Erythematosus – Pipeline by Neovacs SA, H2 2017 74

Systemic Lupus Erythematosus – Pipeline by Nippon Chemiphar Co Ltd, H2 2017 75

Systemic Lupus Erythematosus – Pipeline by Novartis AG, H2 2017 75

Systemic Lupus Erythematosus – Pipeline by Nuevolution AB, H2 2017 76

Systemic Lupus Erythematosus – Pipeline by Omeros Corp, H2 2017 76

Systemic Lupus Erythematosus – Pipeline by Pfizer Inc, H2 2017 77

Systemic Lupus Erythematosus – Pipeline by Principia Biopharma Inc, H2 2017 77

Systemic Lupus Erythematosus – Pipeline by Ra Pharmaceuticals Inc, H2 2017 77

Systemic Lupus Erythematosus – Pipeline by RedHill Biopharma Ltd, H2 2017 78

Systemic Lupus Erythematosus – Pipeline by Sarepta Therapeutics Inc, H2 2017 78

Systemic Lupus Erythematosus – Pipeline by SBI Biotech Co Ltd, H2 2017 79

Systemic Lupus Erythematosus – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 79

Systemic Lupus Erythematosus – Pipeline by TheraMAB LLC, H2 2017 80

Systemic Lupus Erythematosus – Pipeline by TxCell SA, H2 2017 80

Systemic Lupus Erythematosus – Pipeline by UCB SA, H2 2017 80

Systemic Lupus Erythematosus – Pipeline by Xencor Inc, H2 2017 81

Systemic Lupus Erythematosus – Pipeline by XTL Biopharmaceuticals Ltd, H2 2017 81

Systemic Lupus Erythematosus – Pipeline by Zai Lab Ltd, H2 2017 82

Systemic Lupus Erythematosus – Dormant Projects, H2 2017 406

Systemic Lupus Erythematosus – Dormant Projects, H2 2017 (Contd..1), H2 2017 407

Systemic Lupus Erythematosus – Dormant Projects, H2 2017 (Contd..2), H2 2017 408

Systemic Lupus Erythematosus – Dormant Projects, H2 2017 (Contd..3), H2 2017 409

Systemic Lupus Erythematosus – Dormant Projects, H2 2017 (Contd..4), H2 2017 410

Systemic Lupus Erythematosus – Dormant Projects, H2 2017 (Contd..5), H2 2017 411

Systemic Lupus Erythematosus – Discontinued Products, H2 2017 412

Systemic Lupus Erythematosus – Discontinued Products, H2 2017 (Contd..1), H2 2017 413

List of Figures

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H2 2017 20

Number of Products under Development by Companies, H2 2017 21

Number of Products under Development by Universities/Institutes, H2 2017 27

Number of Products by Top 10 Targets, H2 2017 36

Number of Products by Stage and Top 10 Targets, H2 2017 36

Number of Products by Top 10 Mechanism of Actions, H2 2017 41

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 41

Number of Products by Routes of Administration, H2 2017 46

Number of Products by Stage and Routes of Administration, H2 2017 46

Number of Products by Top 10 Molecule Types, H2 2017 48

Number of Products by Stage and Top 10 Molecule Types, H2 2017 48

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports